Vor Biopharma Inc (VOR) Actualités

Form 8-K - Current report

Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the first half of 2025...

Form 8-K - Current report

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report